Evaluation of Platelet Number and Spleen MK Count in Control Mice and Transgenic Mice During and After GCV Treatment
| . | Mean Decrease in Platelet Count (%) . | Mean No. of MK Per Spleen Section . |
|---|---|---|
| Control mice treated with GCV | Unchanged | 20 ± 6 |
| Transgenic mice last stage of GCV treatment | 93% | 1 ± 1 |
| 48 h to 6 d into recovery | 78% | 2 ± 1 |
| 15 to 20 d into recovery | 40% | 16 ± 1 |
| . | Mean Decrease in Platelet Count (%) . | Mean No. of MK Per Spleen Section . |
|---|---|---|
| Control mice treated with GCV | Unchanged | 20 ± 6 |
| Transgenic mice last stage of GCV treatment | 93% | 1 ± 1 |
| 48 h to 6 d into recovery | 78% | 2 ± 1 |
| 15 to 20 d into recovery | 40% | 16 ± 1 |
Each group was composed of 2 mice; the mean number of MK was evaluated on a minimum of 6 sections per spleen.